EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Abstract

Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. Methods An international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned to and participants finally voted on the level of agreement with each item. Results The task force agreed on 5 overarching principles and 11 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); GCs; biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab including biosimilars), abatacept, rituximab, tocilizumab, sarilumab and targeted synthetic (ts) DMARDs, namely the Janus kinase inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib. Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering in sustained clinical remission is provided. Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were all considered. Initially, MTX plus GCs is recommended and on insufficient response to this therapy within 3–6 months, treatment should be based on stratification according to risk factors; With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD should be added to the csDMARD; after careful consideration of risks of MACEs, malignancies and/or thromboembolic events tsDMARDs may also be considered in this phase. If the first bDMARD (or tsDMARD) fails, any other bDMARD (from another or the same class) or tsDMARD (considering risks) is recommended. With sustained remission, DMARDs may be tapered but should not be stopped. Levels of evidence and levels of agreement were high for most recommendations. Conclusions These updated EULAR recommendations provide consensus on RA management including safety, effectiveness and cost.

Keywords

MedicineAntirheumatic drugsRheumatoid arthritisAntirheumatic AgentsArthritisHydroxychloroquineDiseaseBiological drugsIntensive care medicineImmunologyInternal medicine

MeSH Terms

HumansAntirheumatic AgentsBiosimilar PharmaceuticalsArthritisRheumatoidMethotrexateNeoplasmsBiological ProductsDrug TherapyCombination

Affiliated Institutions

Related Publications

Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.

Evangelos Terpos , Kalliopi Fragiadaki , Maria Konsta +3 more

Anti-IL-6 therapy induced suppression of the inflammatory response affects rapidly the disrupted bone homeostasis in active RA. An additional, possibly specific, effect of IL-6 ...

2012 PubMed 83 citations

Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

Yuesong Gong , Lei Chang , Kirsten L. Viola +5 more

A molecular basis for memory failure in Alzheimer's disease (AD) has been recently hypothesized, in which a significant role is attributed to small, soluble oligomers of amyloid...

2003 Proceedings of the National Academy o... 1032 citations

Interleukin 6 Is Required for the Development of Collagen-induced Arthritis

Tonino Alonzi , Elena Fattori , Domenico Lazzaro +6 more

Interleukin-6 (IL-6) is overproduced in the joints of patients with rheumatoid arthritis (RA) and, based on its multiple stimulatory effects on cells of the immune system and on...

1998 The Journal of Experimental Medicine 605 citations

Differential diagnosis of suspected multiple sclerosis: a consensus approach

DH Miller , BG Weinshenker , Massimo Filippi +15 more

Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings. A systematic proc...

2008 Multiple Sclerosis Journal 638 citations

Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation

Marco Cardone , Masahide Yano , Amy S. Rosenberg +1 more

The first case of human transmission of SARS-CoV-2 was reported in China in December 2019. A few months later, this viral infection had spread worldwide and became a pandemic. T...

2020 Frontiers in Immunology 52 citations

Publication Info

Year: 2022
Type: article
Volume: 82
Issue: 1
Pages: 3-18
Citations: 1472
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1472

OpenAlex

Influential

1145

CrossRef

Cite This

APA Style

                            
                                
                                    Josef S Smolen, 
                                
                                    Robert Landewé, 
                                
                                    Sytske Anne Bergstra
                                
                                et al.
                            
                            (2022). 
                            EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. 
                            Annals of the Rheumatic Diseases
                            , 82
                            (1)
                            , 3-18.
                            https://doi.org/10.1136/ard-2022-223356
                        

Identifiers

DOI: 10.1136/ard-2022-223356
PMID: 36357155

Data Quality

Data completeness: 90%